Positive phase 2 study results for TheraVidas'a THVD-102
Posted: Sun Mar 05, 2017 8:10 pm
THVD-102 is a new proprietary oxybutynin 7.5mg plus pilocarpine 7.5mg combination product manufactured by TheraVida:
https://www.businesswire.com/news/home/ ... erhidrosis
https://www.businesswire.com/news/home/ ... erhidrosis